- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT04396860
Testa användningen av immunterapiläkemedlen Ipilimumab och Nivolumab Plus strålbehandling jämfört med den vanliga behandlingen (temozolomid och strålbehandling) för nydiagnostiserat MGMT ometylerat glioblastom
En randomiserad fas II/III öppen studie av Ipilimumab och Nivolumab kontra temozolomid hos patienter med nydiagnostiserat MGMT (tumör O-6-metylguanin DNA-metyltransferas) ometylerat glioblastom
This phase II/III trial compares the usual treatment with radiation therapy and temozolomide to radiation therapy in combination with immunotherapy with ipilimumab and nivolumab in treating patients with newly diagnosed MGMT unmethylated glioblastoma. Radiation therapy uses high energy photons to kill tumor and shrink tumors. Chemotherapy drugs, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Temozolomide, may not work as well for the treatment of tumors that have the unmethylated MGMT. Immunotherapy with monoclonal antibodies called immune checkpoint inhibitors, such as ipilimumab and nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. It is possible that immune checkpoint inhibitors may work better at time of first diagnosis as opposed to when tumor comes back. Giving radiation therapy with ipilimumab and nivolumab may lengthen the time without brain tumor returning or growing and may extend patients' life compared to usual treatment with radiation therapy and temozolomide.
Studieöversikt
Status
Betingelser
Detaljerad beskrivning
PRIMARY OBJECTIVES:
I. To determine if adding ipilimumab and nivolumab to radiotherapy significantly prolongs progression-free survival (PFS) versus adding temozolomide to radiotherapy in patients with newly diagnosed glioblastoma (GBM) without MGMT promoter methylation. (Phase II) II. To determine if adding ipilimumab and nivolumab to radiotherapy significantly prolongs overall survival (OS) versus adding temozolomide to radiotherapy in patients with newly diagnosed GBM without MGMT promoter methylation. (Phase III)
SECONDARY OBJECTIVES:
I. To determine if adding ipilimumab and nivolumab to radiotherapy significantly prolongs PFS versus adding temozolomide to radiotherapy in patients with newly diagnosed GBM without MGMT promoter methylation for the phase III part of the study.
II. To determine if adding ipilimumab and nivolumab to radiotherapy significantly increases the 2-year OS rate versus adding temozolomide to radiotherapy in patients with newly diagnosed GBM without MGMT promoter methylation.
III. To evaluate the safety of adding ipilimumab and nivolumab to radiotherapy via comparative frequency between arms of specific adverse events of interest and frequency summaries for all adverse event types.
IV. To evaluate the effect of adding ipilimumab and nivolumab to radiotherapy versus adding temozolomide to radiotherapy on patient reported outcomes (PROs), as measured by the MD Anderson Symptom Inventory - Brain Tumor (MDASI-BT) in patients with newly diagnosed GBM without MGMT promoter methylation.
V. To evaluate the effect of adding ipilimumab and nivolumab to radiotherapy versus adding temozolomide to radiotherapy on selected Patient Reported Outcomes-Common Terminology Criteria for Adverse Events (PRO-CTCAE) items in patients with newly diagnosed GBM without MGMT promoter methylation.
VI. To evaluate the impact of adding ipilimumab and nivolumab to radiotherapy versus adding temozolomide to radiotherapy on neurocognitive function (NCF) in patients with newly diagnosed GBM without MGMT promoter methylation.
EXPLORATORY OBJECTIVES:
I. To explore biomarkers in pre-treatment archival tumor tissue that may predict efficacy of ipilimumab and nivolumab as measured by OS, PFS, and 2-year OS rate, such as but not limited to:
Ia. PDL1 expression; Ib. Mutational burden. II. To explore (in the two treatment separately) whether the MGMT protein expression correlates with clinical outcomes including OS, PFS, and 2-year OS rate.
III. To evaluate if MGMT protein expression may be predictive of differential treatment effects between the two treatment arms.
OUTLINE: Patients are randomized to 1 of 2 arms.
ARM 1: Patients undergo radiation therapy for 5 days per week (Monday-Friday) for a total of 30 fractions over 6 weeks and simultaneously receive temozolomide orally (PO) daily for 6 weeks. After radiation, patients may wear the Optune device at the discretion of the patient and their treating physician. Beginning 1 month after radiation therapy, patients receive temozolomide on days 1-5. Treatment repeats every 28 days for up to 12 cycles at the discretion of the treating investigator in the absence of disease progression or unacceptable toxicity. Patients also undergo contrast-enhanced brain magnetic resonance imaging (MRI) throughout the trial.
ARM 2: Patients undergo radiation therapy for 5 days per week (Monday-Friday) for a total of 30 fractions over 6 weeks. Starting on the first day of radiation, patients also receive ipilimumab intravenously (IV) over 90 minutes once every 4 weeks (Q4W) for 4 doses and nivolumab IV over 30 minutes every 2 weeks until disease progression. Patients also undergo contrast-enhanced brain MRI throughout the trial.
After completion of study treatment, patients are followed up every 3 months for year 1, then every 4 months for year 2, and then every 6 months thereafter.
Studietyp
Inskrivning (Faktisk)
Fas
- Fas 2
- Fas 3
Kontakter och platser
Studieorter
-
-
Alabama
-
Birmingham, Alabama, Förenta staterna, 35233
- University of Alabama at Birmingham Cancer Center
-
-
Arkansas
-
Little Rock, Arkansas, Förenta staterna, 72205
- University of Arkansas for Medical Sciences
-
-
California
-
Anaheim, California, Förenta staterna, 92806
- Kaiser Permanente-Anaheim
-
Auburn, California, Förenta staterna, 95602
- Sutter Auburn Faith Hospital
-
Auburn, California, Förenta staterna, 95603
- Sutter Cancer Centers Radiation Oncology Services-Auburn
-
Concord, California, Förenta staterna, 94520
- John Muir Medical Center-Concord
-
La Jolla, California, Förenta staterna, 92093
- UC San Diego Moores Cancer Center
-
Loma Linda, California, Förenta staterna, 92354
- Loma Linda University Medical Center
-
Los Angeles, California, Förenta staterna, 90027
- Kaiser Permanente Los Angeles Medical Center
-
Los Angeles, California, Förenta staterna, 90048
- Cedars Sinai Medical Center
-
Ontario, California, Förenta staterna, 91761
- Kaiser Permanente-Ontario
-
Orange, California, Förenta staterna, 92868
- UC Irvine Health/Chao Family Comprehensive Cancer Center
-
Roseville, California, Förenta staterna, 95661
- Sutter Cancer Centers Radiation Oncology Services-Roseville
-
Roseville, California, Förenta staterna, 95661
- Sutter Roseville Medical Center
-
Sacramento, California, Förenta staterna, 95816
- Sutter Medical Center Sacramento
-
Sacramento, California, Förenta staterna, 95817
- University of California Davis Comprehensive Cancer Center
-
Torrance, California, Förenta staterna, 90509
- Torrance Memorial Medical Center
-
Torrance, California, Förenta staterna, 90505
- Torrance Memorial Physician Network - Cancer Care
-
Walnut Creek, California, Förenta staterna, 94598
- John Muir Medical Center-Walnut Creek
-
-
Colorado
-
Colorado Springs, Colorado, Förenta staterna, 80907
- Penrose-Saint Francis Healthcare
-
Denver, Colorado, Förenta staterna, 80210
- AdventHealth Porter
-
Littleton, Colorado, Förenta staterna, 80122
- AdventHealth Littleton
-
Parker, Colorado, Förenta staterna, 80138
- AdventHealth Parker
-
-
Connecticut
-
Hartford, Connecticut, Förenta staterna, 06102
- Hartford Hospital
-
New Britain, Connecticut, Förenta staterna, 06050
- The Hospital of Central Connecticut
-
-
Delaware
-
Lewes, Delaware, Förenta staterna, 19958
- Beebe Medical Center
-
Millville, Delaware, Förenta staterna, 19967
- Beebe South Coastal Health Campus
-
Newark, Delaware, Förenta staterna, 19713
- Helen F Graham Cancer Center
-
Newark, Delaware, Förenta staterna, 19713
- Delaware Clinical and Laboratory Physicians PA
-
Newark, Delaware, Förenta staterna, 19713
- Medical Oncology Hematology Consultants PA
-
Newark, Delaware, Förenta staterna, 19718
- Christiana Care Health System-Christiana Hospital
-
Rehoboth Beach, Delaware, Förenta staterna, 19971
- Beebe Health Campus
-
-
Florida
-
Jacksonville, Florida, Förenta staterna, 32207
- Baptist MD Anderson Cancer Center
-
Orlando, Florida, Förenta staterna, 32803
- AdventHealth Orlando
-
-
Georgia
-
Augusta, Georgia, Förenta staterna, 30912
- Augusta University Medical Center
-
Savannah, Georgia, Förenta staterna, 31405
- Lewis Cancer and Research Pavilion at Saint Joseph's/Candler
-
Savannah, Georgia, Förenta staterna, 31404
- Memorial Health University Medical Center
-
Thomasville, Georgia, Förenta staterna, 31792
- Lewis Hall Singletary Oncology Center
-
-
Hawaii
-
Honolulu, Hawaii, Förenta staterna, 96813
- Queen's Medical Center
-
Honolulu, Hawaii, Förenta staterna, 96817
- The Cancer Center of Hawaii-Liliha
-
Honolulu, Hawaii, Förenta staterna, 96813
- Hawaii Cancer Care Inc - Waterfront Plaza
-
Honolulu, Hawaii, Förenta staterna, 96813
- Queen's Cancer Cenrer - POB I
-
Honolulu, Hawaii, Förenta staterna, 96813
- Straub Clinic and Hospital
-
Honolulu, Hawaii, Förenta staterna, 96813
- University of Hawaii Cancer Center
-
Honolulu, Hawaii, Förenta staterna, 96817
- Hawaii Cancer Care Inc-Liliha
-
Honolulu, Hawaii, Förenta staterna, 96817
- Queen's Cancer Center - Kuakini
-
Honolulu, Hawaii, Förenta staterna, 96826
- Kapiolani Medical Center for Women and Children
-
Honolulu, Hawaii, Förenta staterna, 96813
- Island Urology
-
Kailua, Hawaii, Förenta staterna, 96734
- Castle Medical Center
-
Lihue, Hawaii, Förenta staterna, 96766
- Wilcox Memorial Hospital and Kauai Medical Clinic
-
‘Aiea, Hawaii, Förenta staterna, 96701
- Hawaii Cancer Care - Westridge
-
‘Aiea, Hawaii, Förenta staterna, 96701
- Pali Momi Medical Center
-
‘Aiea, Hawaii, Förenta staterna, 96701
- Queen's Cancer Center - Pearlridge
-
‘Aiea, Hawaii, Förenta staterna, 96701
- The Cancer Center of Hawaii-Pali Momi
-
-
Idaho
-
Boise, Idaho, Förenta staterna, 83712
- Saint Luke's Cancer Institute - Boise
-
Caldwell, Idaho, Förenta staterna, 83605
- Saint Alphonsus Cancer Care Center-Caldwell
-
Fruitland, Idaho, Förenta staterna, 83619
- Saint Luke's Cancer Institute - Fruitland
-
Meridian, Idaho, Förenta staterna, 83642
- Saint Luke's Cancer Institute - Meridian
-
Nampa, Idaho, Förenta staterna, 83687
- Saint Alphonsus Cancer Care Center-Nampa
-
Nampa, Idaho, Förenta staterna, 83687
- Saint Luke's Cancer Institute - Nampa
-
Twin Falls, Idaho, Förenta staterna, 83301
- Saint Luke's Cancer Institute - Twin Falls
-
-
Illinois
-
Bloomington, Illinois, Förenta staterna, 61704
- Illinois CancerCare-Bloomington
-
Canton, Illinois, Förenta staterna, 61520
- Illinois CancerCare-Canton
-
Carthage, Illinois, Förenta staterna, 62321
- Illinois CancerCare-Carthage
-
Centralia, Illinois, Förenta staterna, 62801
- Centralia Oncology Clinic
-
Chicago, Illinois, Förenta staterna, 60611
- Northwestern University
-
Chicago, Illinois, Förenta staterna, 60612
- University of Illinois
-
Danville, Illinois, Förenta staterna, 61832
- Carle at The Riverfront
-
DeKalb, Illinois, Förenta staterna, 60115
- Northwestern Medicine Cancer Center Kishwaukee
-
Decatur, Illinois, Förenta staterna, 62526
- Decatur Memorial Hospital
-
Decatur, Illinois, Förenta staterna, 62526
- Cancer Care Specialists of Illinois - Decatur
-
Effingham, Illinois, Förenta staterna, 62401
- Crossroads Cancer Center
-
Effingham, Illinois, Förenta staterna, 62401
- Carle Physician Group-Effingham
-
Elmhurst, Illinois, Förenta staterna, 60126
- Elmhurst Memorial Hospital
-
Eureka, Illinois, Förenta staterna, 61530
- Illinois CancerCare-Eureka
-
Evanston, Illinois, Förenta staterna, 60201
- NorthShore University HealthSystem-Evanston Hospital
-
Galesburg, Illinois, Förenta staterna, 61401
- Western Illinois Cancer Treatment Center
-
Galesburg, Illinois, Förenta staterna, 61401
- Illinois CancerCare-Galesburg
-
Geneva, Illinois, Förenta staterna, 60134
- Northwestern Medicine Cancer Center Delnor
-
Glenview, Illinois, Förenta staterna, 60026
- NorthShore University HealthSystem-Glenbrook Hospital
-
Highland Park, Illinois, Förenta staterna, 60035
- NorthShore University HealthSystem-Highland Park Hospital
-
Kewanee, Illinois, Förenta staterna, 61443
- Illinois CancerCare-Kewanee Clinic
-
Macomb, Illinois, Förenta staterna, 61455
- Illinois CancerCare-Macomb
-
Mattoon, Illinois, Förenta staterna, 61938
- Carle Physician Group-Mattoon/Charleston
-
Naperville, Illinois, Förenta staterna, 60540
- Edward Hospital/Cancer Center
-
O'Fallon, Illinois, Förenta staterna, 62269
- Cancer Care Center of O'Fallon
-
Ottawa, Illinois, Förenta staterna, 61350
- Illinois CancerCare-Ottawa Clinic
-
Park Ridge, Illinois, Förenta staterna, 60068
- Advocate Lutheran General Hospital
-
Pekin, Illinois, Förenta staterna, 61554
- Illinois CancerCare-Pekin
-
Peoria, Illinois, Förenta staterna, 61636
- Methodist Medical Center of Illinois
-
Peoria, Illinois, Förenta staterna, 61637
- OSF Saint Francis Medical Center
-
Peoria, Illinois, Förenta staterna, 61615
- Illinois CancerCare-Peoria
-
Peru, Illinois, Förenta staterna, 61354
- Illinois CancerCare-Peru
-
Princeton, Illinois, Förenta staterna, 61356
- Illinois CancerCare-Princeton
-
Rockford, Illinois, Förenta staterna, 61114
- UW Health Carbone Cancer Center Rockford
-
Springfield, Illinois, Förenta staterna, 62702
- Southern Illinois University School of Medicine
-
Springfield, Illinois, Förenta staterna, 62702
- Springfield Clinic
-
Springfield, Illinois, Förenta staterna, 62781
- Springfield Memorial Hospital
-
Urbana, Illinois, Förenta staterna, 61801
- Carle Cancer Center
-
Urbana, Illinois, Förenta staterna, 61801
- The Carle Foundation Hospital
-
Warrenville, Illinois, Förenta staterna, 60555
- Northwestern Medicine Cancer Center Warrenville
-
Washington, Illinois, Förenta staterna, 61571
- Illinois CancerCare - Washington
-
-
Indiana
-
Indianapolis, Indiana, Förenta staterna, 46202
- Indiana University/Melvin and Bren Simon Cancer Center
-
Indianapolis, Indiana, Förenta staterna, 46202
- IU Health Methodist Hospital
-
-
Iowa
-
Ames, Iowa, Förenta staterna, 50010
- Mary Greeley Medical Center
-
Ames, Iowa, Förenta staterna, 50010
- McFarland Clinic - Ames
-
Clive, Iowa, Förenta staterna, 50325
- Mercy Cancer Center-West Lakes
-
Clive, Iowa, Förenta staterna, 50325
- UI Health Care Mission Cancer and Blood - West Des Moines Clinic
-
Council Bluffs, Iowa, Förenta staterna, 51503
- Heartland Oncology and Hematology LLP
-
Council Bluffs, Iowa, Förenta staterna, 51503
- Methodist Jennie Edmundson Hospital
-
Creston, Iowa, Förenta staterna, 50801
- Greater Regional Medical Center
-
Des Moines, Iowa, Förenta staterna, 50309
- Iowa Methodist Medical Center
-
Des Moines, Iowa, Förenta staterna, 50314
- Mercy Medical Center - Des Moines
-
Des Moines, Iowa, Förenta staterna, 50314
- Broadlawns Medical Center
-
Des Moines, Iowa, Förenta staterna, 50309
- UI Health Care Mission Cancer and Blood - Des Moines Clinic
-
Des Moines, Iowa, Förenta staterna, 50314
- UI Health Care Mission Cancer and Blood - Laurel Clinic
-
Iowa City, Iowa, Förenta staterna, 52242
- University of Iowa/Holden Comprehensive Cancer Center
-
West Des Moines, Iowa, Förenta staterna, 50266
- Mercy Medical Center-West Lakes
-
-
Kentucky
-
Lexington, Kentucky, Förenta staterna, 40536
- University of Kentucky/Markey Cancer Center
-
-
Louisiana
-
New Orleans, Louisiana, Förenta staterna, 70112
- Tulane University School of Medicine
-
New Orleans, Louisiana, Förenta staterna, 70121
- Ochsner Medical Center Jefferson
-
-
Maine
-
Bangor, Maine, Förenta staterna, 04401
- Eastern Maine Medical Center
-
Bath, Maine, Förenta staterna, 04530
- MaineHealth Coastal Cancer Treatment Center
-
Belfast, Maine, Förenta staterna, 04915
- MaineHealth Waldo Hospital
-
Brewer, Maine, Förenta staterna, 04412
- Lafayette Family Cancer Center-EMMC
-
Portland, Maine, Förenta staterna, 04102
- MaineHealth Maine Medical Center - Portland
-
Rockport, Maine, Förenta staterna, 04856
- Penobscot Bay Medical Center
-
Sanford, Maine, Förenta staterna, 04073
- MaineHealth Cancer Care Center of York County
-
Scarborough, Maine, Förenta staterna, 04074
- Maine Medical Partners Neurology
-
Scarborough, Maine, Förenta staterna, 04074
- MaineHealth Maine Medical Center- Scarborough
-
South Portland, Maine, Förenta staterna, 04106
- MaineHealth Cancer Care and IV Therapy - South Portland
-
-
Maryland
-
Baltimore, Maryland, Förenta staterna, 21201
- University of Maryland/Greenebaum Cancer Center
-
Bel Air, Maryland, Förenta staterna, 21014
- UM Upper Chesapeake Medical Center
-
Columbia, Maryland, Förenta staterna, 21044
- Central Maryland Radiation Oncology in Howard County
-
Glen Burnie, Maryland, Förenta staterna, 21061
- UM Baltimore Washington Medical Center/Tate Cancer Center
-
-
Michigan
-
Ann Arbor, Michigan, Förenta staterna, 48106
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor
-
Brighton, Michigan, Förenta staterna, 48114
- Trinity Health IHA Medical Group Hematology Oncology - Brighton
-
Brighton, Michigan, Förenta staterna, 48114
- Trinity Health Medical Center - Brighton
-
Canton, Michigan, Förenta staterna, 48188
- Trinity Health IHA Medical Group Hematology Oncology - Canton
-
Canton, Michigan, Förenta staterna, 48188
- Trinity Health Medical Center - Canton
-
Chelsea, Michigan, Förenta staterna, 48118
- Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital
-
Chelsea, Michigan, Förenta staterna, 48118
- Chelsea Hospital
-
Dearborn, Michigan, Förenta staterna, 48124
- Corewell Health Dearborn Hospital
-
Detroit, Michigan, Förenta staterna, 48236
- Henry Ford Health Saint John Hospital
-
Flint, Michigan, Förenta staterna, 48503
- Hurley Medical Center
-
Flint, Michigan, Förenta staterna, 48503
- Genesys Hurley Cancer Institute
-
Grand Rapids, Michigan, Förenta staterna, 49503
- Corewell Health Grand Rapids Hospitals - Butterworth Hospital
-
Kalamazoo, Michigan, Förenta staterna, 49007
- West Michigan Cancer Center
-
Kalamazoo, Michigan, Förenta staterna, 49007
- Bronson Methodist Hospital
-
Kalamazoo, Michigan, Förenta staterna, 49048
- Beacon Kalamazoo
-
Livonia, Michigan, Förenta staterna, 48154
- Trinity Health Saint Mary Mercy Livonia Hospital
-
Pontiac, Michigan, Förenta staterna, 48341
- Michigan Healthcare Professionals Pontiac
-
Royal Oak, Michigan, Förenta staterna, 48073
- Corewell Health William Beaumont University Hospital
-
Saginaw, Michigan, Förenta staterna, 48604
- Oncology Hematology Associates of Saginaw Valley PC
-
Saginaw, Michigan, Förenta staterna, 48601
- MyMichigan Medical Center Saginaw
-
Tawas City, Michigan, Förenta staterna, 48764
- MyMichigan Medical Center Tawas
-
Troy, Michigan, Förenta staterna, 48085
- Corewell Health Beaumont Troy Hospital
-
Warren, Michigan, Förenta staterna, 48093
- Henry Ford Health Warren Hospital
-
West Branch, Michigan, Förenta staterna, 48661
- Saint Mary's Oncology/Hematology Associates of West Branch
-
Wyoming, Michigan, Förenta staterna, 49519
- University of Michigan Health - West
-
Ypsilanti, Michigan, Förenta staterna, 48197
- Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus
-
-
Minnesota
-
Bemidji, Minnesota, Förenta staterna, 56601
- Sanford Joe Lueken Cancer Center
-
Burnsville, Minnesota, Förenta staterna, 55337
- Fairview Ridges Hospital
-
Burnsville, Minnesota, Förenta staterna, 55337
- Minnesota Oncology - Burnsville
-
Coon Rapids, Minnesota, Förenta staterna, 55433
- Mercy Hospital
-
Edina, Minnesota, Förenta staterna, 55435
- Fairview Southdale Hospital
-
Fridley, Minnesota, Förenta staterna, 55432
- Unity Hospital
-
Maple Grove, Minnesota, Förenta staterna, 55369
- Fairview Clinics and Surgery Center Maple Grove
-
Maplewood, Minnesota, Förenta staterna, 55109
- Minnesota Oncology Hematology PA-Maplewood
-
Minneapolis, Minnesota, Förenta staterna, 55415
- Hennepin County Medical Center
-
Minneapolis, Minnesota, Förenta staterna, 55454
- Health Partners Inc
-
Saint Louis Park, Minnesota, Förenta staterna, 55416
- Park Nicollet Clinic - Saint Louis Park
-
Saint Paul, Minnesota, Förenta staterna, 55101
- Regions Hospital
-
Saint Paul, Minnesota, Förenta staterna, 55102
- United Hospital
-
Stillwater, Minnesota, Förenta staterna, 55082
- Lakeview Hospital
-
-
Mississippi
-
Jackson, Mississippi, Förenta staterna, 39216
- University of Mississippi Medical Center
-
Southhaven, Mississippi, Förenta staterna, 38671
- Baptist Memorial Hospital and Cancer Center-Desoto
-
-
Missouri
-
Cape Girardeau, Missouri, Förenta staterna, 63703
- Saint Francis Medical Center
-
-
Montana
-
Billings, Montana, Förenta staterna, 59101
- Billings Clinic Cancer Center
-
Bozeman, Montana, Förenta staterna, 59715
- Bozeman Health Deaconess Hospital
-
Butte, Montana, Förenta staterna, 59701
- Saint James Community Hospital and Cancer Treatment Center
-
Great Falls, Montana, Förenta staterna, 59405
- Benefis Sletten Cancer Institute
-
Kalispell, Montana, Förenta staterna, 59901
- Logan Health Medical Center
-
-
Nebraska
-
Bellevue, Nebraska, Förenta staterna, 68123
- Nebraska Medicine-Bellevue
-
Lincoln, Nebraska, Förenta staterna, 68516
- Cancer Partners of Nebraska
-
Omaha, Nebraska, Förenta staterna, 68114
- Nebraska Methodist Hospital
-
Omaha, Nebraska, Förenta staterna, 68198
- University of Nebraska Medical Center
-
Omaha, Nebraska, Förenta staterna, 68118
- Nebraska Medicine-Village Pointe
-
-
New Hampshire
-
Lebanon, New Hampshire, Förenta staterna, 03756
- Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center
-
-
New Jersey
-
Hackensack, New Jersey, Förenta staterna, 07601
- Hackensack University Medical Center
-
Livingston, New Jersey, Förenta staterna, 07039
- Saint Barnabas Medical Center
-
Morristown, New Jersey, Förenta staterna, 07960
- Morristown Medical Center
-
Neptune City, New Jersey, Förenta staterna, 07753
- Jersey Shore Medical Center
-
New Brunswick, New Jersey, Förenta staterna, 08903
- Rutgers Cancer Institute of New Jersey
-
Pennington, New Jersey, Förenta staterna, 08534
- Capital Health Medical Center-Hopewell
-
Summit, New Jersey, Förenta staterna, 07902
- Overlook Hospital
-
-
New York
-
New York, New York, Förenta staterna, 10032
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center
-
New York, New York, Förenta staterna, 10065
- NYP/Weill Cornell Medical Center
-
New York, New York, Förenta staterna, 10016
- Laura and Isaac Perlmutter Cancer Center at NYU Langone
-
Rochester, New York, Förenta staterna, 14642
- University of Rochester
-
Syracuse, New York, Förenta staterna, 13210
- State University of New York Upstate Medical University
-
West Islip, New York, Förenta staterna, 11795
- Good Samaritan University Hospital
-
-
North Carolina
-
Charlotte, North Carolina, Förenta staterna, 28203
- Carolinas Medical Center/Levine Cancer Institute
-
Charlotte, North Carolina, Förenta staterna, 28210
- Atrium Health Pineville/LCI-Pineville
-
Concord, North Carolina, Förenta staterna, 28025
- Atrium Health Cabarrus/LCI-Concord
-
-
North Dakota
-
Bismarck, North Dakota, Förenta staterna, 58501
- Sanford Bismarck Medical Center
-
Fargo, North Dakota, Förenta staterna, 58122
- Sanford Roger Maris Cancer Center
-
Fargo, North Dakota, Förenta staterna, 58122
- Sanford Broadway Medical Center
-
-
Ohio
-
Akron, Ohio, Förenta staterna, 44304
- Summa Health System - Akron Campus
-
Cleveland, Ohio, Förenta staterna, 44106
- Case Western Reserve University
-
Cleveland, Ohio, Förenta staterna, 44195
- Cleveland Clinic Foundation
-
Columbus, Ohio, Förenta staterna, 43214
- Riverside Methodist Hospital
-
Dublin, Ohio, Förenta staterna, 43016
- Dublin Methodist Hospital
-
-
Oklahoma
-
Lawton, Oklahoma, Förenta staterna, 73505
- Cancer Centers of Southwest Oklahoma Research
-
Oklahoma City, Oklahoma, Förenta staterna, 73104
- University of Oklahoma Health Sciences Center
-
-
Oregon
-
Clackamas, Oregon, Förenta staterna, 97015
- Clackamas Radiation Oncology Center
-
Clackamas, Oregon, Förenta staterna, 97015
- Providence Cancer Institute Clackamas Clinic
-
Gresham, Oregon, Förenta staterna, 97030
- Legacy Mount Hood Medical Center
-
Newberg, Oregon, Förenta staterna, 97132
- Providence Newberg Medical Center
-
Portland, Oregon, Förenta staterna, 97210
- Legacy Good Samaritan Hospital and Medical Center
-
Portland, Oregon, Förenta staterna, 97213
- Providence Portland Medical Center
-
Portland, Oregon, Förenta staterna, 97225
- Providence Saint Vincent Medical Center
-
Portland, Oregon, Förenta staterna, 97227
- Kaiser Permanente Northwest
-
Tualatin, Oregon, Förenta staterna, 97062
- Legacy Meridian Park Hospital
-
-
Pennsylvania
-
Allentown, Pennsylvania, Förenta staterna, 18103
- Lehigh Valley Hospital-Cedar Crest
-
Broomall, Pennsylvania, Förenta staterna, 19008
- Crozer-Keystone Regional Cancer Center at Broomall
-
Chadds Ford, Pennsylvania, Förenta staterna, 19317
- Christiana Care Health System-Concord Health Center
-
Lancaster, Pennsylvania, Förenta staterna, 17601
- Lancaster General Ann B Barshinger Cancer Institute
-
Lancaster, Pennsylvania, Förenta staterna, 17602
- Lancaster General Hospital
-
Monroeville, Pennsylvania, Förenta staterna, 15146
- Forbes Hospital
-
Philadelphia, Pennsylvania, Förenta staterna, 19107
- Thomas Jefferson University Hospital
-
Pittsburgh, Pennsylvania, Förenta staterna, 15212
- Allegheny General Hospital
-
Pittsburgh, Pennsylvania, Förenta staterna, 15232
- University of Pittsburgh Cancer Institute (UPCI)
-
Pittsburgh, Pennsylvania, Förenta staterna, 15232
- UPMC-Shadyside Hospital
-
West Reading, Pennsylvania, Förenta staterna, 19611
- Reading Hospital
-
Wexford, Pennsylvania, Förenta staterna, 15090
- Wexford Health and Wellness Pavilion
-
-
South Carolina
-
Rock Hill, South Carolina, Förenta staterna, 29730
- Rock Hill Radiation Therapy Center
-
-
South Dakota
-
Pierre, South Dakota, Förenta staterna, 57501
- Avera Cancer Institute at Pierre
-
Sioux Falls, South Dakota, Förenta staterna, 57105
- Avera Cancer Institute
-
Sioux Falls, South Dakota, Förenta staterna, 57117-5134
- Sanford USD Medical Center - Sioux Falls
-
Sioux Falls, South Dakota, Förenta staterna, 57104
- Sanford Cancer Center Oncology Clinic
-
-
Tennessee
-
Collierville, Tennessee, Förenta staterna, 38017
- Baptist Memorial Hospital and Cancer Center-Collierville
-
Memphis, Tennessee, Förenta staterna, 38120
- Baptist Memorial Hospital and Cancer Center-Memphis
-
-
Texas
-
Houston, Texas, Förenta staterna, 77030
- Memorial Hermann Texas Medical Center
-
San Antonio, Texas, Förenta staterna, 78229
- University of Texas Health Science Center at San Antonio
-
-
Utah
-
American Fork, Utah, Förenta staterna, 84003
- American Fork Hospital / Huntsman Intermountain Cancer Center
-
Cedar City, Utah, Förenta staterna, 84720
- Sandra L Maxwell Cancer Center
-
Logan, Utah, Förenta staterna, 84321
- Logan Regional Hospital
-
Murray, Utah, Förenta staterna, 84107
- Intermountain Medical Center
-
Ogden, Utah, Förenta staterna, 84403
- McKay-Dee Hospital Center
-
Provo, Utah, Förenta staterna, 84604
- Utah Valley Regional Medical Center
-
Riverton, Utah, Förenta staterna, 84065
- Riverton Hospital
-
Salt Lake City, Utah, Förenta staterna, 84112
- Huntsman Cancer Institute/University of Utah
-
Salt Lake City, Utah, Förenta staterna, 84143
- LDS Hospital
-
St. George, Utah, Förenta staterna, 84770
- Saint George Regional Medical Center
-
-
Vermont
-
Berlin Corners, Vermont, Förenta staterna, 05602
- Central Vermont Medical Center/National Life Cancer Treatment
-
Burlington, Vermont, Förenta staterna, 05401
- University of Vermont Medical Center
-
Burlington, Vermont, Förenta staterna, 05405
- University of Vermont and State Agricultural College
-
-
Virginia
-
Fairfax, Virginia, Förenta staterna, 22031
- Inova Schar Cancer Institute
-
Richmond, Virginia, Förenta staterna, 23298
- VCU Massey Comprehensive Cancer Center
-
South Hill, Virginia, Förenta staterna, 23970
- VCU Community Memorial Health Center
-
-
Washington
-
Seattle, Washington, Förenta staterna, 98101
- Virginia Mason Medical Center
-
Vancouver, Washington, Förenta staterna, 98686
- Legacy Salmon Creek Hospital
-
Vancouver, Washington, Förenta staterna, 98684
- Legacy Cancer Institute Medical Oncology and Day Treatment
-
-
West Virginia
-
Wheeling, West Virginia, Förenta staterna, 26003
- Wheeling Hospital/Schiffler Cancer Center
-
-
Wisconsin
-
Burlington, Wisconsin, Förenta staterna, 53105
- Aurora Cancer Care-Southern Lakes VLCC
-
Germantown, Wisconsin, Förenta staterna, 53022
- Aurora Health Care Germantown Health Center
-
Grafton, Wisconsin, Förenta staterna, 53024
- Aurora Cancer Care-Grafton
-
Green Bay, Wisconsin, Förenta staterna, 54311
- Aurora BayCare Medical Center
-
Johnson Creek, Wisconsin, Förenta staterna, 53038
- University of Wisconsin Carbone Cancer Center - Johnson Creek
-
Kenosha, Wisconsin, Förenta staterna, 53142
- Aurora Cancer Care-Kenosha South
-
Madison, Wisconsin, Förenta staterna, 53792
- University of Wisconsin Carbone Cancer Center - University Hospital
-
Marinette, Wisconsin, Förenta staterna, 54143
- Aurora Bay Area Medical Group-Marinette
-
Milwaukee, Wisconsin, Förenta staterna, 53209
- Aurora Cancer Care-Milwaukee
-
Milwaukee, Wisconsin, Förenta staterna, 53215
- Aurora Saint Luke's Medical Center
-
Milwaukee, Wisconsin, Förenta staterna, 53233
- Aurora Sinai Medical Center
-
Minocqua, Wisconsin, Förenta staterna, 54548
- Marshfield Medical Center - Minocqua
-
New Richmond, Wisconsin, Förenta staterna, 54017
- Cancer Center of Western Wisconsin
-
Oshkosh, Wisconsin, Förenta staterna, 54904
- Vince Lombardi Cancer Clinic - Oshkosh
-
Racine, Wisconsin, Förenta staterna, 53406
- Aurora Cancer Care-Racine
-
Sheboygan, Wisconsin, Förenta staterna, 53081
- Vince Lombardi Cancer Clinic-Sheboygan
-
Summit, Wisconsin, Förenta staterna, 53066
- Aurora Medical Center in Summit
-
Two Rivers, Wisconsin, Förenta staterna, 54241
- Vince Lombardi Cancer Clinic-Two Rivers
-
Wauwatosa, Wisconsin, Förenta staterna, 53226
- Aurora Cancer Care-Milwaukee West
-
West Allis, Wisconsin, Förenta staterna, 53227
- Aurora West Allis Medical Center
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
-
PRIOR TO STEP 1 REGISTRATION:
-
No known IDH mutation. (If tested before step 1 registration, patients known to have IDH mutation in the tumor on local or other testing are ineligible and should not be registered)
-
Availability of formalin-fixed paraffin-embedded (FFPE) tumor tissue block and hematoxylin & eosin (H&E) stained slide to be sent for central pathology review for confirmation of histology and MGMT promoter methylation status. Note that tissue for central pathology review and central MGMT assessment must be received by the New York University (NYU) Center for Biospecimen Research and Development (CBRD) on or before postoperative calendar day 23. If tissue cannot be received by postoperative calendar day 23, then patients may NOT enroll on this trial as central pathology review will not be complete in time for the patient to start treatment no later than 6 weeks following surgery. Results of central pathology review and central MGMT analysis will generally be conveyed to NRG Oncology within 10 business days of receipt of tissue. Note: In the event of an additional tumor resection(s), tissue must be received within 23 days of the most recent resection and the latest resection must have been performed within 30 days after the initial resection. Surgical resection (partial or complete) is required; a limited biopsy is not allowed because it will not provide sufficient tissue for MGMT analysis
- Note: The central pathology review and central MGMT results determine eligibility. Therefore, patients may be offered the opportunity to consent REGARDLESS of local pathology and MGMT results, and consent can occur BEFORE local pathology interpretation is finalized and BEFORE local MGMT testing is conducted
-
Contrast-enhanced brain MRI within 3 days after surgery
- MRI with Axial T2 weighted FLAIR {preferred} or T2 turbo spin echo (TSE)/fast spin echo (FSE) and 3-dimensional (3D) contrast-enhanced T1 sequences are required
- 3D pre contrast-enhanced T1 sequences are strongly suggested
-
Women of childbearing potential (WOCBP) and men who are sexually active with WOCBP must be willing to use an adequate method of contraception hormonal or barrier method of birth control; or abstinence during and after treatment
-
The patient or a legally authorized representative must provide study-specific informed consent prior to study entry
-
PRIOR TO STEP 2 REGISTRATION:
-
Histopathologically proven diagnosis of glioblastoma (or gliosarcoma as a subtype of glioblastoma) confirmed by central pathology review
- Note: diagnoses of "Molecular glioblastoma" per the Consortium to Inform Molecular and Practical Approaches to Central Nervous System (CNS) Tumor Taxonomy (c-IMPACT-NOW) criteria or "CNS grade 4" per the World Health Organization (WHO) 2021 criteria are NOT relevant
-
MGMT promoter without methylation confirmed by central pathology review. Note: Patients with tissue that is insufficient or inadequate for analysis, fails MGMT testing, or has indeterminate or methylated MGMT promoter are excluded.
- Note: central pathology review and central MGMT results determine eligibility; local pathology or MGMT results cannot be used for eligibility/randomization
- Note: patients with methylated MGMT may be considered for enrollment on NRG-BN011
-
IDH mutation testing by at least one method (such as immunohistochemistry for IDH1 R132H) must be performed as part of standard of care and no mutation must be found (i.e IDH wildtype). (If a mutation is identified then the patient will be ineligible and must be registered as ineligible at step 2.)
- Note: this test is not being performed in real time as part of central review and will not be provided to sites from a centrally performed test
-
History/physical examination within 28 days prior to step 2 registration
-
Karnofsky Performance Status (KPS) >= 70 within 28 days prior to step 2 registration
-
Neurologic function assessment within 28 days prior to step 2 registration
-
Age >= 18 years
-
Hemoglobin >= 10 g/dl (Note: the use of transfusion or other intervention to achieve hemoglobin [Hgb] >= 10.0 g/dl is acceptable) (within 7 days prior to step 2 registration)
-
Leukocytes >= 2,000/mm^3 (within 7 days prior to step 2 registration)
-
Absolute neutrophil count >= 1,500/mm^3 (within 7 days prior to step 2 registration)
-
Platelets >= 100,000/mm^3 (within 7 days prior to step 2 registration)
-
Total bilirubin =< 1.5 x institutional/lab upper limit of normal (ULN) (within 7 days prior to step 2 registration)
-
Aspartate transaminase (AST) (serum glutamic-oxaloacetic transaminase [SGOT]) =< 2.5 x ULN (within 7 days prior to step 2 registration)
-
Alanine transferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 2.5 x ULN (within 7 days prior to step 2 registration)
-
Serum creatinine =< 1.5 x ULN OR creatinine clearance (CrCl) >= 50 mL/min (if using the Cockcroft-Gault formula) (within 7 days prior to step 2 registration)
-
For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated. Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load
-
For women of childbearing potential (WOCBP), negative serum or urine pregnancy test within 7 days prior to step 2 registration. Note that it may need to be repeated if not also within 3 days prior to treatment start
- Women of childbearing potential (WOCBP) is defined as any female who has experienced menarche and who has not undergone surgical sterilization (hysterectomy or bilateral oophorectomy) or who is not postmenopausal. Menopause is defined clinically as 12 months of amenorrhea in a woman over 45 in the absence of other biological or physiological causes
Exclusion Criteria:
-
Prior therapy for tumor except for resection. For example, prior chemotherapy, immunotherapy, or targeted therapy for GBM or lower grade glioma is disallowed (including but not limited to temozolomide, lomustine, bevacizumab, any viral therapy, ipilimumab or other CTLA-4 antibody, PD-1 antibody, CD-137 agonist, CD40 antibody, PDL-1 or 2 antibody, vaccine therapy, polio or similar viral injection as treatment for the tumor, and/or any other antibody or drug specifically targeting T-cell co-stimulation or immune checkpoint pathways) as is prior Laser interstitial thermal therapy (LITT), Gliadel wafer, radiotherapy, radiosurgery, gamma knife, cyber knife, vaccine or other immunotherapy, brachytherapy, or convection enhanced delivery;
- Note that 5-aminolevulinic acid (ALA)-mediated fluorescent guided resection (FGR) photodynamic therapy (PDT) or fluorescein administered prior to/during surgery to aid resection is not exclusionary and is not considered a chemotherapy or intracerebral agent
-
Current or planned treatment with any other investigational agents for the study cancer
-
Definitive clinical or radiologic evidence of metastatic disease outside the brain
-
Prior invasive malignancy (except non-melanomatous skin cancer, cervical cancer in situ and melanoma in situ) unless disease free for a minimum of 2 years
-
Prior radiotherapy to the head or neck that would result in overlap of radiation therapy fields
-
Pregnancy and nursing females due to the potential teratogenic effects and potential risk for adverse events in nursing infants
-
History of severe hypersensitivity reaction to any monoclonal antibody
-
History of allergic reactions attributed to compounds of similar chemical or biologic composition to ipilimumab, nivolumab, or temozolomide
-
On any dose of any systemically administered (oral, rectal, intravenous) corticosteroid within 3 days prior to step 2 registration. Inhaled, topical, and ocular corticosteroids are allowed without limitation but must be recorded. Note that treatment with systemically administered corticosteroid after initiating study treatment is allowed as needed
-
Patients with known immune impairment who may be unable to respond to anti-CTLA 4 antibody
-
History of interstitial lung disease including but not limited to sarcoidosis or pneumonitis
-
Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, defined as New York Heart Association functional classification III/IV (Note: Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association functional classification), unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
-
Known history of testing positive for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS)
-
Patients with active autoimmune disease or history of autoimmune disease that might recur, which may affect vital organ function or require immune suppressive treatment including systemic corticosteroids, are excluded, as are patients on active immunosuppressive therapy. These include but are not limited to: patients with a history of immune-related neurologic disease, CNS or motor neuropathy, multiple sclerosis, autoimmune (demyelinating) neuropathy, Guillain-Barre syndrome, myasthenia gravis; systemic autoimmune disease such as autoimmune vasculitis [e.g., Wegener's Granulomatosis]), systemic lupus erythematosus (SLE), connective tissue diseases (e.g., systemic progressive sclerosis), scleroderma, inflammatory bowel disease (IBD), Crohn's, ulcerative colitis, hepatitis; and patients with a history of toxic epidermal necrolysis (TEN), Stevens-Johnson syndrome, or phospholipid syndrome, Hashimoto's thyroiditis, autoimmune hepatitis are excluded because of the risk of recurrence or exacerbation of disease
-
Exceptions: patients with a history of the following conditions are not excluded, unless receiving active immunosuppressive therapy:
-
Vitiligo
-
Type I diabetes
-
Rheumatoid arthritis and other arthropathies
-
Sjogren's syndrome and psoriasis controlled with topical medication and patients with positive serology, such as antinuclear antibodies (ANA)
- Anti-thyroid antibodies should be evaluated for the presence of target organ involvement and potential need for systemic treatment but should otherwise be eligible
-
-
-
Patients who have evidence of active or acute diverticulitis, intra-abdominal abscess, gastrointestinal (GI) obstruction and abdominal carcinomatosis which are known risk factors for bowel perforation are also excluded
-
Current or planned therapy with warfarin
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Aktiv komparator: Arm I (radiation therapy, temozolomide)
Patients undergo radiation therapy for 5 days per week (Monday-Friday) for a total of 30 fractions over 6 weeks and simultaneously receive temozolomide PO daily for 6 weeks. After radiation, patients may wear the Optune device at the discretion of the patient and their treating physician. Beginning 1 month after radiation therapy, patients receive temozolomide on days 1-5. Treatment repeats every 28 days for up to 12 cycles at the discretion of the treating investigator in the absence of disease progression or unacceptable toxicity. Patients also undergo contrast-enhanced brain MRI throughout the trial. |
Ancillary studies
Andra namn:
Ancillary studies Given PO
Andra namn:
Undergo radiation therapy
Andra namn:
Undergo contrast-enhanced brain MRI
Andra namn:
Wear Optune device
Andra namn:
|
|
Experimentell: Arm II (radiation therapy, ipilimumab, nivolumab)
Patients undergo radiation therapy for 5 days per week (Monday-Friday) for a total of 30 fractions over 6 weeks. Starting on the first day of radiation, patients also receive ipilimumab IV over 90 minutes Q4W for 4 doses and nivolumab IV over 30 minutes every 2 weeks until disease progression. Patients also undergo contrast-enhanced brain MRI throughout the trial. |
Ancillary studies
Andra namn:
Given IV
Andra namn:
Ancillary studies Given IV
Andra namn:
Undergo radiation therapy
Andra namn:
Undergo contrast-enhanced brain MRI
Andra namn:
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Progression-free Survival (PFS) (Phase II)
Tidsram: From randomization to date of progression, death, or last known follow-up, whichever occurs first. Maximum follow-up time was 19.3 months.
|
Disease progression was confirmed by central review and defined using an adaptation of the Response Assessment in Neuro-Oncology criteria (Wen et al, J Clin Oncol. 2010 Apr 10;28(11):1963-72. doi: 10.1200/JCO.2009.26.3541. Epub 2010 Mar 15) with modification such that the first MRI performed following completion of radiotherapy is the baseline MRI for determination of radiographic disease. Progression-free survival time is defined as time from randomization to the date of first progression, death, or the last progression assessment with no documented progression (censored). Progression-free survival rates were estimated using the Kaplan-Meier method. |
From randomization to date of progression, death, or last known follow-up, whichever occurs first. Maximum follow-up time was 19.3 months.
|
|
Overall Survival (OS) (Phase III)
Tidsram: From randomization to date of death or last known follow-up. Maximum follow-up time was 19.3 months.
|
Overall survival time is defined as time from randomization to the date of death from any cause or last known follow-up (censored). Overall survival rates were to be estimated by the Kaplan-Meier method. |
From randomization to date of death or last known follow-up. Maximum follow-up time was 19.3 months.
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
PFS for the Entire Cohort (Phase II/III)
Tidsram: From randomization to date of progression, death, or last known follow-up. Maximum follow-up time was 19.3 months.
|
Disease progression was confirmed by central review and defined using an adaptation of the Response Assessment in Neuro-Oncology criteria (Wen et al, J Clin Oncol. 2010 Apr 10;28(11):1963-72. doi: 10.1200/JCO.2009.26.3541. Epub 2010 Mar 15) with modification such that the first MRI performed following completion of radiotherapy is the baseline MRI for determination of radiographic disease. Progression-free survival time is defined as time from randomization to the date of first progression, death, or the last progression assessment with no documented progression (censored). Progression-free survival rates were estimated using the Kaplan-Meier method. |
From randomization to date of progression, death, or last known follow-up. Maximum follow-up time was 19.3 months.
|
|
Overall Survival at 2 Years
Tidsram: From randomization to two years
|
Overall survival time is defined as time from randomization to the date of death from any cause or last known follow-up (censored). Two-year survival rates were to be estimated by the Kaplan-Meier method. |
From randomization to two years
|
|
Number of Participants by Highest Grade Adverse Event Reported
Tidsram: From randomization to date of last known follow-up. Maximum follow-up time was 19.3 months.
|
Common Terminology Criteria for Adverse Events (version 5.0) grades adverse event severity from 1=mild to 5=death. Summary data is provided in this outcome measure; see Adverse Events Module for specific adverse event data. |
From randomization to date of last known follow-up. Maximum follow-up time was 19.3 months.
|
|
Change in MD Anderson Symptom Inventory for Brain Tumor (MDASI-BT) Symptom Severity at Six Months (Patient Reported Outcomes)
Tidsram: Baseline and six months
|
The MD Anderson Symptom Inventory-Brain Tumor (MDASI-BT) Symptom Severity subscale is a patient-reported outcome measure that assesses the severity of symptoms experienced by patients with brain tumors over the previous 24 hours. Possible subscale scores range from 0 to 10, with higher scores indicating a worse outcome. The change score was calculated as the 6-month value minus the baseline value. A negative change reflects improvement at 6 months and a positive change reflects decline at 6 months. |
Baseline and six months
|
|
Time to Neurocognitive Failure
Tidsram: From randomization to date of failure, disease progression, death, or last known follow-up whichever occurred first. Maximum follow-up time was 55.0 months.
|
Neurocognitive failure is defined as the first instance of neurocognitive decline in any of six assessments, as determined by the reliable change index: Hopkins Verbal Learning Test-Revised (HVLT-R) Total Recall, HVLT-R Delayed Recall, HVLT-R Delayed Recognition, Trail Making Test (TMT) part A, TMT part B, and Controlled Oral Word Association (COWA). Failure time is defined as time from randomization to failure, disease progression or death (competing events), or last follow-up (censored). Neurocognitive failure rates and median failure times are estimated using the cumulative incidence method. Participants with no baseline or no follow-up neurocognitive function data were censored at day 1. |
From randomization to date of failure, disease progression, death, or last known follow-up whichever occurred first. Maximum follow-up time was 55.0 months.
|
|
Number of Participants With Most Severe Response for Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) at 6 Months
Tidsram: Six months
|
Questions refer to the participants' experiences for the past 7 days of a given symptom in terms of frequency (never, rarely, occasionally, frequently, almost constantly), severity (none, mild, moderate, severe, very severe), interference with usual or daily activities (not at all, a little bit, somewhat, quite a bit, very much). The last response of each of the lists is the most severe response. |
Six months
|
Andra resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
OS (om studien avbryts i fas II)
Tidsram: I slutet av fas II av studien
|
I slutet av fas II av studien
|
|
|
Tumor Biomarker Analyses
Tidsram: Up to 4 years
|
Will assess PD-L1 expression and mutational burden expression specifically. |
Up to 4 years
|
|
MGMT Protein Expression
Tidsram: Up to 4 years
|
Will assess the prognostic value of MGMT protein expression (in terms of predicting clinical outcomes such as PFS, OS, and 2-year OS rate) in the two treatment arms, separately. In addition, will evaluate if MGMT protein expression may be predictive of differential treatment effects between the two treatment arms. Correlation methods and survival modeling will be used to address these questions. |
Up to 4 years
|
Samarbetspartners och utredare
Sponsor
Samarbetspartners
Utredare
- Huvudutredare: Andrew B Lassman, NRG Oncology
Publikationer och användbara länkar
Allmänna publikationer
- Woroniecka K, Fecci PE. Immuno-synergy? Neoantigen vaccines and checkpoint blockade in glioblastoma. Neuro Oncol. 2020 Sep 29;22(9):1233-1234. doi: 10.1093/neuonc/noaa170. No abstract available.
- Lassman AB, Polley MC, Iwamoto FM, Sloan AE, Wang TJC, Aldape KD, Wefel JS, Gondi V, Gutierrez AN, Manasawala MH, Gilbert MR, Sulman EP, Wolchok JD, Green RM, Neil EC, Lukas RV, Goldlust SA, Snuderl M, Galbraith K, Dignam JJ, Won M, Mehta MP. Dual Immune Check Point Blockade in MGMT-Unmethylated Newly Diagnosed Glioblastoma: NRG Oncology BN007, a Randomized Phase II/III Clinical Trial. J Clin Oncol. 2025 Sep 20;43(27):3032-3040. doi: 10.1200/JCO-25-00618. Epub 2025 Aug 8.
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Faktisk)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
- Neoplasmer
- Neoplasmer efter histologisk typ
- Neoplasmer, körtel och epitel
- Gliom
- Neoplasmer, neuroepitelial
- Neuroektodermala tumörer
- Neoplasmer, könsceller och embryonala
- Neoplasmer, nervvävnad
- Gliosarkom
- Aminosyror, peptider och proteiner
- Proteiner
- Organiska kemikalier
- Heterocykliska föreningar, 1-ring
- Heterocykliska föreningar
- Undersökningstekniker
- Terapeutik
- Azoler
- Farmakologiska åtgärder
- Kemiska åtgärder och användningar
- Biologiska faktorer
- Fysiska fenomen
- Dacarbazin
- Triazenes
- Imidazoler
- Antikroppar, monoklonal, humaniserad
- Antikroppar, monoklonal
- Antikroppar
- Immunglobuliner
- Immunoproteiner
- Blodproteiner
- Serumglobuliner
- Globuliner
- Specialanvändning av kemikalier
- Kemitekniker, analytiska
- Spektrumanalys
- Receptorer, cellytan
- Membranproteiner
- Antigen
- Antigen, yta
- Biomarkörer
- Diagnostisk användning av kemikalier
- Receptorer, immunologiska
- Antigen, differentiering, T-lymfocyt
- Antigener, differentiering
- Immunkontrollproteiner
- Costimulatory och hämmande T-cellreceptorer
- Temozolomid
- Nivolumab
- Ipilimumab
- Strålbehandling
- Strålning
- Magnetresonansspektroskopi
- Kontrastmedium
- CTLA-4-antigen
Andra studie-ID-nummer
- NCI-2020-03404
- U10CA180868 (U.S.S. NIH-anslag/kontrakt)
- NCI-2020-03404 (Registeridentifierare: CTRP (Clinical Trial Reporting Program))
- NRG-BN007 (Annan identifierare: CTEP)
- NRG-BN007 (Annan identifierare: NRG Oncology)
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
IPD-planbeskrivning
NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page.
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .